Cediranib西地尼布,288383-20-0

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Cediranib

CAS No. : 288383-20-0

MCE 国际站：Cediranib

产品活性：Cediranib (AZD2171) 是高选择性，有口服活性的 VEGFR2 抑制剂，对Flt1，KDR，Flt4，PDGFRα，PDGFRβ，c-Kit的 IC₅₀ 值分别为小于1， 小于3，5，5，36，2nM。

研究领域：Protein Tyrosine Kinase/RTK  |  Autophagy

作用靶点：VEGFR  |  Autophagy  |  PDGFR

In Vitro: In human umbilical vein endothelial cells, Cediranib inhibits VEGF-stimulated proliferation and KDR phosphorylation with IC₅₀ values of 0.4 and 0.5 nM, respectively. In a fibroblast/endothelial cell coculture model of vessel sprouting, Cediranib also reduces vessel area, length, and branching at subnanomolar concentrations.

In Vivo: Once-daily oral administration of Cediranib ablates experimental (VEGF-induced) angiogenesis and inhibits endochondral ossification in bone or corpora luteal development in ovary; physiologic processes that are highly dependent upon neovascularization. The growth of established human tumor xenografts (colon, lung, prostate, breast, and ovary) in athymic mice is inhibited dose-dependently by Cediranib, with chronic administration of 1.5 mg per kg per day producing statistically significant inhibition in all models. A histologic analysis of Calu-6 lung tumors treated with Cediranib reveals a reduction in microvessel density within 52 hours that becomes progressively greater with the duration of treatment. These changes are indicative of vascular regression within tumors.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  CNS-Penetrant Compound Library  |  Autophagy Compound Library  |  Drug Repurposing Compound Library  |  Differentiation Inducing Compound Library  |  Reprogramming Compound Library  |  Anti-COVID-19 Compound Library  |  Orally Active Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Angiogenesis-Related Compound Library  |  Anti-Liver Cancer Compound Library   |  Rare Diseases Drug Library  |  Anti-Colorectal Cancer Compound Library   |  Human Metabolite Library  |  Anti-Prostate Cancer Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Heterocyclic Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Cytokine Inhibitors Library  |  Cell Death Library  |  Sorafenib  |  Lenvatinib  |  Sunitinib  |  Regorafenib  |  Nintedanib  |  Bevacizumab  |  Imatinib  |  Semaxinib  |  Cabozantinib  |  Ponatinib  |  Axitinib  |  Midostaurin  |  Chloramphenicol  |  Pazopanib  |  PD173074  |  Crenolanib  |  5Z-7-Oxozeaenol  |  Linifanib  |  Tanshinone IIA  |  Vandetanib  |  Foretinib  |  SU 5402  |  Avapritinib  |  Fruquintinib  |  SPHINX31  |  Masitinib  |  CP-673451

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds